A Complex Post-Transplant Puzzle: Successful Intervention in Chronic Allograft Dysfunction with Portal Biliopathy and Portal Vein Thrombosis

Authors

  • Adhiraj. B
  • Shanmugachandru. S
  • Immanuvel. T
  • Jacintha Abisha Angel.S
  • K. Karthickeyan
  • P. Shanmuga Sundaram
  • M.K. Sundar Sri

Keywords:

N/A

Abstract

We report a case of a 38-year-old female who presented with gastrointestinal symptoms eight years after a deceased donor liver transplantation performed for autoimmune hepatitis. She was found to have chronic allograft dysfunction complicated by portal biliopathy, portal vein thrombosis, ascites, and anemia. Her management involved percutaneous transhepatic biliary drainage (PTBD), terlipressin infusion, blood product transfusions, and optimization of immunosuppressive therapy. This case highlights the complex nature of long-term complications following liver transplantation and emphasizes the importance of multidisciplinary management in such cases.

Downloads

Download data is not yet available.

References

Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology. 1998;28:638–645. - PubMed

2Anand AC, Hubscher SG, Gunson BK, McMaster P, Neuberger JM. Timing, significance, and prognosis of late acute liver allograft rejection. Transplantation. 1995;60:1098–1103. - PubMed

Desai M, Neuberger J. Chronic liver allograft dysfunction. Transplant Proc. 2009;41:773–776. - PubMed

Wyatt JI. Liver transplant pathology: messages for the non-specialist. Histopathology. 2010;57:333–341. - PubMed

Neuberger J. Chronic allograft dysfunction: diagnosis and management. Is it always progressive? Liver Transpl. 2005;(11 Suppl 2):S63–S68. – PubMed

Poupon RE, Poupon R, Balkau B, UDC-PBC Study Group Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med. 1994;330:1342–1347. - PubMed

Combes B, Carithers RL, Maddrey WC, et al. A randomized double blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1995;22:759–766. - PubMed

Lindor KD, Poupon R, Heathcote EJ, et al. Ursodeoxycholic acid for primary biliary cirrhosis. Lancet. 2000;355:657–658. - PubMed

Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology. 1997;113:884–890. - PubMed

Goulis J, Leandro G, Burroughs A. Randomized controlled trials of ursodeoxycholic acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet. 1999;354:1053–1060. – PubMed

Yang J, Xu MQ, Yan LN, Chen XB, Liu J. Zinc finger protein A20 protects rats against chronic liver allograft dysfunction. World Journal of Gastroenterology. 2012;18(27):3537–3550. - PMC – PubMed.

Pappo O, Ramos H, Starzl TE, Fung JJ, Demetris AJ. Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation. American Journal of Surgical Pathology. 1995;19(2):192–206. - PMC – PubMed.

Neuberger J. Chronic allograft dysfunction: diagnosis and management. Is it always progressive? Liver Transplantation. 2005;11(11, supplement 2):S63–S68. – PubMed.

Friedman BH, Wolf JH, Wang L, et al. Serum cytokine profiles associated with early allograft dysfunction in patients undergoing liver transplantation. Liver Transplantation. 2012;18(2):166–176. - PMC – PubMed.

Khettry U, Backer A, Ayata G, Lewis WD, Jenkins RL, Gordon FD. Centrilobular histopathologic changes in liver transplant biopsies. Human Pathology. 2002;33(3):270–276. – PubMed.

Downloads

Published

2025-07-18

How to Cite

1.
B A, S S, T I, Angel.S JA, Karthickeyan K, Sundaram PS, Sri MS. A Complex Post-Transplant Puzzle: Successful Intervention in Chronic Allograft Dysfunction with Portal Biliopathy and Portal Vein Thrombosis. J Neonatal Surg [Internet]. 2025Jul.18 [cited 2025Oct.3];14(32S):5757-60. Available from: https://www.jneonatalsurg.com/index.php/jns/article/view/8365

Issue

Vol. 14 No. 32S (2025): Journal of Neonatal Surgery

Section

Original Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.

Terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.